Find out everything you need to know about the latest COVID-19 booster shot here >

Showing 1 - 7 of 7 David Victor
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination with Obeticholic Acid in Subjects with Primary Biliary Cholangitis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC). ... Read more >

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)

Status: Enrolling

Investigator: David Victor

Study Coordinator: Rene Andrade Ruiz

Phone: 832.768.1924

The primary objective of the Core Study is to evaluate the efficacy of volixibat versus placebo for the treatment of pruritus (as measured by the change in the Adult ItchRO tool) in participants with PSC on the basis of the following endpoint: ... Read more >

A randomized, double-blind, placebo-controlled, multicenter, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2/fibrosis 3 stage of liver fibrosis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH). ... Read more >

A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH). ... Read more >

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The ... Read more >

The Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)

Status: Enrolling

Investigator: David Victor

Study Coordinator: Rene Andrade Ruiz

Phone: 832.768.1924

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which t ... Read more >